Evidence map›Paper›PMID 42200915›Full record

ArticleNeuroSci2026

PART as a Negative Outcome Modifier of Glioblastoma Treatment, Case Report.

Ross Terada, Jennifer Dailey, Sherry Yan, Michael Punsoni, Eric T Wong

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in NeuroSci, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ross TeradaDivision of Hematology/Oncology, Department of Medicine, Brown University Health, Providence, RI 02903, USA.ORCID 0009-0005-1211-6451
Jennifer DaileyDivision of Neuropathology, Department of Pathology, Brown University Health, Providence, RI 02903, USA.
Sherry YanDepartment of Radiation Oncology, Boston Medical Center, Boston, MA 02118, USA.
Michael PunsoniDivision of Neuropathology, Department of Pathology, Brown University Health, Providence, RI 02903, USA.
Eric T WongDivision of Hematology/Oncology, Department of Medicine, Brown University Health, Providence, RI 02903, USA.ORCID 0000-0001-7112-6207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere neurocognitive decline is often seen in elderly glioblastoma patients after treatment with radiation and chemotherapy. But the mechanism behind their deterioration is unclear. We describe one such patient with concomitant primary age-related tauopathy (PART) in bilateral hippocampi. CASE PRESENTATION: An 88-year-old woman experienced unsteadiness, memory loss, and slurred speech that was caused by an epithelioid glioblastoma with wild-type isocitrate dehydrogenase-1 and methylated promoter of

conclusionsUndiagnosed tauopathy could be a negative modifier of glioblastoma treatment. The identification of PART and other tauopathies as risk factors in the elderly population may be important to guide treatment decision.

Indexed as

case reportglioblastomaPARTtauopathy

Identifiers

PMID42200915
PMCPMC13214797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.